NovoCure Director Martin J. Madden Receives RSUs and Option Award

What Happened

• Martin J. Madden, a director of NovoCure Ltd (NVCR), received two equity awards reported on a Form 4 dated 2026-06-05 for transactions on 2026-06-03: 11,610 restricted stock units (RSUs) and a derivative award covering 16,999 shares (options). Both awards are reported at $0 per share (grant value reported as $0 on the Form 4). There were no sales or purchases of existing shares — these are grants/awards (compensation).

Key Details

• Transaction date(s): 2026-06-03; Form 4 filed: 2026-06-05 (timely within the SEC two-business-day rule).
• Awards: 11,610 RSUs (footnote F1) and 16,999-share derivative award (footnote F2).
• Reported price: $0.00 per share; reported dollar value on the Form 4 = $0.
• Vesting/exercise notes:
  • F1: RSUs vest 100% on the earlier of the first anniversary of the grant or the day before NovoCure’s 2027 annual general meeting.
  • F2: The derivative award (options) will fully vest and become exercisable on the earlier of the first anniversary of the grant or the day before the 2027 AGM.
• Shares owned after the transactions are not specified in this filing.

Context

• These are compensation grants to a director, not open-market purchases or sales. Grants at $0 are standard for RSUs/options and reflect awards rather than a cash purchase; they do not indicate an immediate cash outlay or sale. The options vesting schedule means the shares aren’t exercisable immediately but will be on the schedule described in the footnotes.